Biopharmaceutical company developing novel small molecule therapeutics.
Akarna Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases.
Akarna’s lead program is a potential best-in-class therapeutic for the treatment of non-alcoholic steatohepatitis (NASH). On August 26, 2016 Akarna was acquired by Allergan for an USD 50m upfront cash payment and success-based development, approval and sales milestone payments.
Industry
Biotech
Status
Realised
Location
UK